REPORT ID 434

EMEA (Europe, Middle East and Africa) Amyloidosis Therapeutics Market Report 2019

Publish Date
2019
Pages
113
Format
Electronic (PDF)

In this report, the EMEA Amyloidosis Therapeutics market is valued at USD   XX million in 2019 and is expected to reach USD  XX million by the end of 2025, growing at a CAGR of  XX% between 2019 and 2025.

Geographically, this report split EMEA into Europe, the Middle East and Africa, With sales (K Pcs), revenue (Million USD), market share and growth rate of Amyloidosis Therapeutics for these regions, from   2019 to 2025 (forecast)
    Europe: Germany, France, UK, Russia, Italy and Benelux;
    Middle East: Saudi Arabia, Israel, UAE and Iran;
    Africa: South Africa, Nigeria, Egypt and Algeria.

EMEA Amyloidosis Therapeutics market competition by top manufacturers/players, with Amyloidosis Therapeutics sales volume (K Pcs), price (USD/Pcs), revenue (Million USD) and market share for each manufacturer/player; the top players including
    Pfizer Inc.
    ProteoTech, Inc.
    Alnylam Pharmaceuticals, Inc.
    Arcturus Therapeutics, Inc
    Bellus Health Inc.
    Bsim2
    Celgene Corporation
    Millennium Pharmaceuticals, Inc.
    Onyx Pharmaceuticals, Inc.
    GlaxoSmithKline Plc
    Isis Pharmaceuticals, Inc.
    Prothena Corporation Plc
    SOM Innovation Biotech SL

On the basis of product, this report displays the sales volume, revenue, product price, market share and growth rate of each type, primarily split into
    AG-10
    ALN-ANG
    ALN-TTRsc02
    CAEL-101
    canakinumab
    Others

On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate for each application, including
    AL amyloidosis
    AA amyloidoses
    ATTR amyloidoses
    Others

If you have any special requirements, please let us know and we will offer you the report as you want.

 
			   
Table of Contents

EMEA (Europe, Middle East and Africa) Amyloidosis Therapeutics Market  Report 2019
1 Amyloidosis Therapeutics Overview
    1.1 Product Overview and Scope of Amyloidosis Therapeutics
    1.2 Classification of Amyloidosis Therapeutics
        1.2.1 EMEA Amyloidosis Therapeutics Market Size (Sales) Comparison by Type ( 2014-2024)
        1.2.2 EMEA Amyloidosis Therapeutics Market Size (Sales) Market Share by Type (Product Category)  in 2018
        1.2.3 AG-10
        1.2.4 ALN-ANG
        1.2.5 ALN-TTRsc02
        1.2.6 CAEL-101
        1.2.7 canakinumab
        1.2.8 Others
    1.3 EMEA Amyloidosis Therapeutics Market by Application/End Users
        1.3.1 EMEA Amyloidosis Therapeutics Sales (Volume) and Market Share Comparison by Application ( 2014-2024
        1.3.2 AL amyloidosis
        1.3.3 AA amyloidoses
        1.3.4 ATTR amyloidoses
        1.3.5 Others
    1.4 EMEA Amyloidosis Therapeutics Market by Region
        1.4.1 EMEA Amyloidosis Therapeutics Market Size (Value) Comparison by Region ( 2014-2024)
        1.4.2 Europe Status and Prospect ( 2014-2024)
        1.4.3 Middle East Status and Prospect ( 2014-2024)
        1.4.4 Africa Status and Prospect ( 2014-2024)
    1.5 EMEA Market Size (Value and Volume) of Amyloidosis Therapeutics ( 2014-2024)
        1.5.1 EMEA Amyloidosis Therapeutics Sales and Growth Rate ( 2014-2024)
        1.5.2 EMEA Amyloidosis Therapeutics Revenue and Growth Rate ( 2014-2024)

2 EMEA Amyloidosis Therapeutics Competition by Manufacturers/Players/Suppliers, Region, Type and Application
    2.1 EMEA Amyloidosis Therapeutics Market Competition by Players/Manufacturers
        2.1.1 EMEA Amyloidosis Therapeutics Sales Volume and Market Share of Major Players ( 2014-2019)
        2.1.2 EMEA Amyloidosis Therapeutics Revenue and Share by Players ( 2014-2019)
        2.1.3 EMEA Amyloidosis Therapeutics Sale Price by Players ( 2014-2019)
    2.2 EMEA Amyloidosis Therapeutics (Volume and Value) by Type/Product Category
        2.2.1 EMEA Amyloidosis Therapeutics Sales and Market Share by Type ( 2014-2019)
        2.2.2 EMEA Amyloidosis Therapeutics Revenue and Market Share by Type ( 2014-2019)
        2.2.3 EMEA Amyloidosis Therapeutics Sale Price by Type ( 2014-2019)
    2.3 EMEA Amyloidosis Therapeutics (Volume) by Application
    2.4 EMEA Amyloidosis Therapeutics (Volume and Value) by Region
        2.4.1 EMEA Amyloidosis Therapeutics Sales and Market Share by Region ( 2014-2019)
        2.4.2 EMEA Amyloidosis Therapeutics Revenue and Market Share by Region ( 2014-2019)
        2.4.3 EMEA Amyloidosis Therapeutics Sales Price by Region ( 2014-2019)

3 Europe Amyloidosis Therapeutics (Volume, Value and Sales Price), by Players, Countries, Type and Application
    3.1 Europe Amyloidosis Therapeutics Sales and Value ( 2014-2019)
        3.1.1 Europe Amyloidosis Therapeutics Sales Volume and Growth Rate ( 2014-2019)
        3.1.2 Europe Amyloidosis Therapeutics Revenue and Growth Rate ( 2014-2019)
    3.2 Europe Amyloidosis Therapeutics Sales and Market Share by Type
    3.3 Europe Amyloidosis Therapeutics Sales and Market Share by Application
    3.4 Europe Amyloidosis Therapeutics Sales Volume and Value (Revenue) by Countries
        3.4.1 Europe Amyloidosis Therapeutics Sales Volume by Countries ( 2014-2019)
        3.4.2 Europe Amyloidosis Therapeutics Revenue by Countries ( 2014-2019)
        3.4.3 Germany Amyloidosis Therapeutics Sales and Growth Rate ( 2014-2019)
        3.4.4 France Amyloidosis Therapeutics Sales and Growth Rate ( 2014-2019)
        3.4.5 UK Amyloidosis Therapeutics Sales and Growth Rate ( 2014-2019)
        3.4.6 Russia Amyloidosis Therapeutics Sales and Growth Rate ( 2014-2019)
        3.4.7 Italy Amyloidosis Therapeutics Sales and Growth Rate ( 2014-2019)
        3.4.8 Benelux Amyloidosis Therapeutics Sales and Growth Rate ( 2014-2019)

4 Middle East Amyloidosis Therapeutics (Volume, Value and Sales Price), by Region, Type and Application
    4.1 Middle East Amyloidosis Therapeutics Sales and Value ( 2014-2019)
        4.1.1 Middle East Amyloidosis Therapeutics Sales Volume and Growth Rate ( 2014-2019)
        4.1.2 Middle East Amyloidosis Therapeutics Revenue and Growth Rate ( 2014-2019)
    4.2 Middle East Amyloidosis Therapeutics Sales and Market Share by Type
    4.3 Middle East Amyloidosis Therapeutics Sales and Market Share by Application
    4.4 Middle East Amyloidosis Therapeutics Sales Volume and Value (Revenue) by Countries
        4.4.1 Middle East Amyloidosis Therapeutics Sales Volume by Countries ( 2014-2019)
        4.4.2 Middle East Amyloidosis Therapeutics Revenue by Countries ( 2014-2019)
        4.4.3 Saudi Arabia Amyloidosis Therapeutics Sales and Growth Rate ( 2014-2019)
        4.4.4 Israel Amyloidosis Therapeutics Sales and Growth Rate ( 2014-2019)
        4.4.5 UAE Amyloidosis Therapeutics Sales and Growth Rate ( 2014-2019)
        4.4.6 Iran Amyloidosis Therapeutics Sales and Growth Rate ( 2014-2019)

5 Africa Amyloidosis Therapeutics (Volume, Value and Sales Price) by Players, Countries, Type and Application
    5.1 Africa Amyloidosis Therapeutics Sales and Value ( 2014-2019)
        5.1.1 Africa Amyloidosis Therapeutics Sales Volume and Growth Rate ( 2014-2019)
        5.1.2 Africa Amyloidosis Therapeutics Revenue and Growth Rate ( 2014-2019)
    5.2 Africa Amyloidosis Therapeutics Sales and Market Share by Type
    5.3 Africa Amyloidosis Therapeutics Sales and Market Share by Application
    5.4 Africa Amyloidosis Therapeutics Sales Volume and Value (Revenue) by Countries
        5.4.1 Africa Amyloidosis Therapeutics Sales Volume by Countries ( 2014-2019)
        5.4.2 Africa Amyloidosis Therapeutics Revenue by Countries ( 2014-2019)
        5.4.3 South Africa Amyloidosis Therapeutics Sales and Growth Rate ( 2014-2019)
        5.4.4 Nigeria Amyloidosis Therapeutics Sales and Growth Rate ( 2014-2019)
        5.4.5 Egypt Amyloidosis Therapeutics Sales and Growth Rate ( 2014-2019)
        5.4.6 Algeria Amyloidosis Therapeutics Sales and Growth Rate ( 2014-2019)

6 EMEA Amyloidosis Therapeutics Manufacturers/Players Profiles and Sales Data
    6.1 Pfizer Inc.
        6.1.1 Company Basic Information, Manufacturing Base and Competitors
        6.1.2 Amyloidosis Therapeutics Product Type, Application and Specification
            6.1.2.1 Product A
            6.1.2.2 Product B
        6.1.3 Pfizer Inc. Amyloidosis Therapeutics Sales, Revenue, Price and Gross Margin ( 2014-2019)
        6.1.4 Main Business/Business Overview
    6.2 ProteoTech, Inc.
        6.2.1 Company Basic Information, Manufacturing Base and Competitors
        6.2.2 Amyloidosis Therapeutics Product Type, Application and Specification
            6.2.2.1 Product A
            6.2.2.2 Product B
        6.2.3 ProteoTech, Inc. Amyloidosis Therapeutics Sales, Revenue, Price and Gross Margin ( 2014-2019)
        6.2.4 Main Business/Business Overview
    6.3 Alnylam Pharmaceuticals, Inc.
        6.3.1 Company Basic Information, Manufacturing Base and Competitors
        6.3.2 Amyloidosis Therapeutics Product Type, Application and Specification
            6.3.2.1 Product A
            6.3.2.2 Product B
        6.3.3 Alnylam Pharmaceuticals, Inc. Amyloidosis Therapeutics Sales, Revenue, Price and Gross Margin ( 2014-2019)
        6.3.4 Main Business/Business Overview
    6.4 Arcturus Therapeutics, Inc
        6.4.1 Company Basic Information, Manufacturing Base and Competitors
        6.4.2 Amyloidosis Therapeutics Product Type, Application and Specification
            6.4.2.1 Product A
            6.4.2.2 Product B
        6.4.3 Arcturus Therapeutics, Inc Amyloidosis Therapeutics Sales, Revenue, Price and Gross Margin ( 2014-2019)
        6.4.4 Main Business/Business Overview
    6.5 Bellus Health Inc.
        6.5.1 Company Basic Information, Manufacturing Base and Competitors
        6.5.2 Amyloidosis Therapeutics Product Type, Application and Specification
            6.5.2.1 Product A
            6.5.2.2 Product B
        6.5.3 Bellus Health Inc. Amyloidosis Therapeutics Sales, Revenue, Price and Gross Margin ( 2014-2019)
        6.5.4 Main Business/Business Overview
    6.6 Bsim2
        6.6.1 Company Basic Information, Manufacturing Base and Competitors
        6.6.2 Amyloidosis Therapeutics Product Type, Application and Specification
            6.6.2.1 Product A
            6.6.2.2 Product B
        6.6.3 Bsim2 Amyloidosis Therapeutics Sales, Revenue, Price and Gross Margin ( 2014-2019)
        6.6.4 Main Business/Business Overview
    6.7 Celgene Corporation
        6.7.1 Company Basic Information, Manufacturing Base and Competitors
        6.7.2 Amyloidosis Therapeutics Product Type, Application and Specification
            6.7.2.1 Product A
            6.7.2.2 Product B
        6.7.3 Celgene Corporation Amyloidosis Therapeutics Sales, Revenue, Price and Gross Margin ( 2014-2019)
        6.7.4 Main Business/Business Overview
    6.8 Millennium Pharmaceuticals, Inc.
        6.8.1 Company Basic Information, Manufacturing Base and Competitors
        6.8.2 Amyloidosis Therapeutics Product Type, Application and Specification
            6.8.2.1 Product A
            6.8.2.2 Product B
        6.8.3 Millennium Pharmaceuticals, Inc. Amyloidosis Therapeutics Sales, Revenue, Price and Gross Margin ( 2014-2019)
        6.8.4 Main Business/Business Overview
    6.9 Onyx Pharmaceuticals, Inc.
        6.9.1 Company Basic Information, Manufacturing Base and Competitors
        6.9.2 Amyloidosis Therapeutics Product Type, Application and Specification
            6.9.2.1 Product A
            6.9.2.2 Product B
        6.9.3 Onyx Pharmaceuticals, Inc. Amyloidosis Therapeutics Sales, Revenue, Price and Gross Margin ( 2014-2019)
        6.9.4 Main Business/Business Overview
    6.10 GlaxoSmithKline Plc
        6.10.1 Company Basic Information, Manufacturing Base and Competitors
        6.10.2 Amyloidosis Therapeutics Product Type, Application and Specification
            6.10.2.1 Product A
            6.10.2.2 Product B
        6.10.3 GlaxoSmithKline Plc Amyloidosis Therapeutics Sales, Revenue, Price and Gross Margin ( 2014-2019)
        6.10.4 Main Business/Business Overview
    6.11 Isis Pharmaceuticals, Inc.
    6.12 Prothena Corporation Plc
    6.13 SOM Innovation Biotech SL

7 Amyloidosis Therapeutics Manufacturing Cost Analysis
    7.1 Amyloidosis Therapeutics Key Raw Materials Analysis
        7.1.1 Key Raw Materials
        7.1.2 Price Trend of Key Raw Materials
        7.1.3 Key Suppliers of Raw Materials
        7.1.4 Market Concentration Rate of Raw Materials
    7.2 Proportion of Manufacturing Cost Structure
        7.2.1 Raw Materials
        7.2.2 Labor Cost
        7.2.3 Manufacturing Expenses
    7.3 Manufacturing Process Analysis of Amyloidosis Therapeutics

8 Industrial Chain, Sourcing Strategy and Downstream Buyers
    8.1 Amyloidosis Therapeutics Industrial Chain Analysis
    8.2 Upstream Raw Materials Sourcing
    8.3 Raw Materials Sources of Amyloidosis Therapeutics Major Manufacturers  in 2018
    8.4 Downstream Buyers

9 Marketing Strategy Analysis, Distributors/Traders
    9.1 Marketing Channel
        9.1.1 Direct Marketing
        9.1.2 Indirect Marketing
        9.1.3 Marketing Channel Development Trend
    9.2 Market Positioning
        9.2.1 Pricing Strategy
        9.2.2 Brand Strategy
        9.2.3 Target Client
    9.3 Distributors/Traders List

10 Market Effect Factors Analysis
    10.1 Technology Progress/Risk
        10.1.1 Substitutes Threat
        10.1.2 Technology Progress in Related Industry
    10.2 Consumer Needs/Customer Preference Change
    10.3 Economic/Political Environmental Change

11 EMEA Amyloidosis Therapeutics Market Forecast ( 2019-2025)
    11.1 EMEA Amyloidosis Therapeutics Sales, Revenue and Price Forecast ( 2019-2025)
        11.1.1 EMEA Amyloidosis Therapeutics Sales and Growth Rate Forecast ( 2019-2025)
        11.1.2 EMEA Amyloidosis Therapeutics Revenue and Growth Rate Forecast ( 2019-2025)
        11.1.3 EMEA Amyloidosis Therapeutics Price and Trend Forecast ( 2019-2025)
    11.2 EMEA Amyloidosis Therapeutics Sales, Revenue and Growth Rate Forecast by Region ( 2019-2025)
    11.3 Europe Amyloidosis Therapeutics Sales, Revenue and Growth Rate Forecast by Region ( 2019-2025)
    11.4 Middle Eastt Amyloidosis Therapeutics Sales, Revenue and Growth Rate Forecast by Region ( 2019-2025)
    11.5 Africa Amyloidosis Therapeutics Sales, Revenue and Growth Rate Forecast by Region ( 2019-2025)
    11.6 EMEA Amyloidosis Therapeutics Sales Forecast by Type ( 2019-2025)
    11.7 EMEA Amyloidosis Therapeutics Sales Forecast by Application ( 2019-2025)

12 Research Findings and Conclusion

13 Appendix
    13.1 Methodology/Research Approach
        13.1.1 Research Programs/Design
        13.1.2 Market Size Estimation
        13.1.3 Market Breakdown and Data Triangulation
    13.2 Data Source
        13.2.1 Secondary Sources
        13.2.2 Primary Sources
    13.3 Disclaimer